M. Alauddin et al., 2015 - Google Patents
Current and future trends in early detection of pancreatic cancer: molecular targets and PET probesM. Alauddin et al., 2015
- Document ID
- 12197546427895747350
- Author
- M. Alauddin M
- De Palatis L
- Publication year
- Publication venue
- Current Medicinal Chemistry
External Links
Snippet
Early detection of pancreatic cancer has been a long-standing challenge in determining prognosis and management of the deadly disease. Although the incidence of pancreatic cancer is low (2% of all malignancies), it is the fourth leading cause of deaths attributable to …
- 201000002528 pancreatic cancer 0 title abstract description 125
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2223/00—Investigating materials by wave or particle radiation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ming et al. | Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer | |
| Schwenck et al. | Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT | |
| Mankoff et al. | Tumor-specific positron emission tomography imaging in patients:[18F] fluorodeoxyglucose and beyond | |
| Ulaner | PET/CT for patients with breast cancer: where is the clinical impact? | |
| Komar et al. | Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness | |
| M. Alauddin et al. | Current and future trends in early detection of pancreatic cancer: molecular targets and PET probes | |
| Rohren et al. | Clinical applications of PET in oncology | |
| Quon et al. | FDG-PET and beyond: molecular breast cancer imaging | |
| Yap et al. | Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography | |
| Yamamoto et al. | Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer | |
| Margolis et al. | Molecular imaging techniques in body imaging | |
| Michalski et al. | Molecular imaging in cancer treatment | |
| Specht et al. | Advances in molecular imaging for breast cancer detection and characterization | |
| McKnight et al. | 89Zr‐ImmunoPET companion diagnostics and their impact in clinical drug development | |
| Kim et al. | Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous 18F-fluorocholine PET/MRI for primary prostate cancer characterization | |
| De Bree et al. | Advances in imaging in the work-up of head and neck cancer patients | |
| Vaidya et al. | The continuing evolution of molecular functional imaging in clinical oncology: the road to precision medicine and radiogenomics (Part I) | |
| Kurihara et al. | Molecular imaging using PET for breast cancer | |
| Wu et al. | Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer | |
| Cintolo et al. | Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response | |
| Oehr et al. | Imaging of prostate cancer | |
| Rioja et al. | Role of positron emission tomography in urological oncology | |
| Mankoff | Molecular imaging as a tool for translating breast cancer science | |
| Lawrentschuk et al. | Functional imaging of renal cell carcinoma | |
| Mahajan et al. | Clinical applications of PET/CT in oncology |